HIGH-DOSE ORAL METHYLPREDNISOLONE THERAPY IN CHILDHOOD HEMANGIOMAS

The authors report their experience with high-dose oral methylprednisolone therapy (HDMP)in 15 infants with complicated hemangiomas. The starting dose for methylprednisolone was 30 mg/kg/day for 5 days, then the dose was tapered gradually every 5 days to 20, 10, 5, 2.5, and finally to 1 mg/kg/day. T...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric hematology and oncology 2001, Vol.18 (5), p.335-341
Main Authors: Uysal, Kamer Mutafo lu, Olgun, Nur, Erbay, Ay e, Sarialio lu, Faik
Format: Article
Language:English
Subjects:
Administration, Oral
Biological and medical sciences
Bones, joints and connective tissue. Antiinflammatory agents
Corticosteroids
Female
Hemangioma
Hemangiomas
High-DOSEMETHYLPREDNISOLONE
Humans
Infant
Infant, Newborn
Male
Medical sciences
Methylprednisolone - administration & dosage
Methylprednisolone - adverse effects
Methylprednisolone - therapeutic use
Neoplasms - drug therapy
Pharmacology. Drug treatments
Subglottic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The authors report their experience with high-dose oral methylprednisolone therapy (HDMP)in 15 infants with complicated hemangiomas. The starting dose for methylprednisolone was 30 mg/kg/day for 5 days, then the dose was tapered gradually every 5 days to 20, 10, 5, 2.5, and finally to 1 mg/kg/day. Therapy was then stopped and the patients were followed. An initial response was evident in 12 patients. Nine out of 12 responders showed regrowth signs. After regrowth, 4 cases received prednisolone at doses between 1 to 5 mg/kg/day and 3 patients received a second course with HDMP as additional corticosteroid therapy. Overall, 9 out of 15 cases were responders; very good and good responses were obtained in 5, partial response in 4, and therapy failure in 5 cases. One child was not available for evaluation of response. A very rapid initial response was observed in subglottic and periocular hemangiomas. Side effects were not serious and resolved after discontinuation of treatment. Although the number of patients is small in this study, overall response rate with HDMP regimen seems not to be superior to the regimens that use lower doses (5 mg/kg/day), but it provides a high initial response rate and the duration of therapy is short. Therefore, it may be useful for treating hemangiomas that fail to respond with low doses, especially in centers with limited resources where other treatment modalities cannot be used at the moment.
ISSN:0888-0018
1521-0669
DOI:10.1080/088800101300312609